{"DataElement":{"publicId":"2005546","version":"4","preferredName":"Common Toxicity Criteria Adverse Event Nodal Arrhythmia Supraventricular Arrhythmia Grade","preferredDefinition":"in CTC category Cardiac Arrhythmia, assessment of the severity of an adverse event for the supraordinate term supraventricular and nodal arrhythmia - select using a graded scale.","longName":"CTC_AE_NODA_SUPA_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2193065","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Nodal Arrhythmia Supraventricular Arrhythmia","preferredDefinition":"information related to the CTC adverse event of nodal and supraventricular arrhythmia.","longName":"CTC_AE_NODARH_SUPARH","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2660857","version":"1","preferredName":"Nodal Arrhythmia Supraventricular Arrhythmia","preferredDefinition":"Nodal arrhythmia is arrythmia occurring when the atrioventricular node or surrounding junctional tissue is acting as pacemaker.:An arrhythmia originating from centers proximal to the ventricles, namely in the atrium, A-V node, or A-V junction, in contrast to arrhythmias arising in the ventricles themselves. -- 2003","longName":"C27045:C0428974","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Arrhythmia by ECG Finding","conceptCode":"C27045","definition":"An electrocardiographic finding of an arrhythmia originating from within the atrioventricular node.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Supraventricular Arrhythmia","conceptCode":"C0428974","definition":"An arrhythmia originating from centers proximal to the ventricles, namely in the atrium, A-V node, or A-V junction, in contrast to arrhythmias arising in the ventricles themselves. -- 2003","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E73C82-D86F-5882-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAA83722-80FF-511A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017746","version":"3","preferredName":"Common Toxicity Criteria Adverse Event Nodal Arrhythmia Supraventricular Arrhythmia Grade","preferredDefinition":"in CTC category Cardiac Arrhythmia, assessment of the severity of an adverse event for the supraordinate term supraventricular and nodal arrhythmia - select using a graded scale.","longName":"CTC_AE_NODA_SUPA_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CC2-2600-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Non-urgent medical intervention indicated","ValueMeaning":{"publicId":"2566508","version":"1","preferredName":"Non-urgent medical intervention indicated","longName":"2566508","preferredDefinition":"Non-urgent medical intervention indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CC4-2600-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)","ValueMeaning":{"publicId":"2562833","version":"1","preferredName":"life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)","longName":"2562833","preferredDefinition":"life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C27E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CC6-2600-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"Asymptomatic, intervention not indicated","ValueMeaning":{"publicId":"2566455","version":"1","preferredName":"Asymptomatic, intervention not indicated","longName":"2566455","preferredDefinition":"Asymptomatic, intervention not indicated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-11","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CC8-2600-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker)","ValueMeaning":{"publicId":"2569327","version":"1","preferredName":"Symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker)","longName":"2569327","preferredDefinition":"Symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DBDC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-16","endDate":null,"createdBy":"PWEST","dateCreated":"2004-04-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CCA-2600-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4B1DA87-7CCC-2600-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4B1DA87-7CBE-2600-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-12","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Supraventri","type":"Preferred Question Text","description":"CTC Adverse Event Supraventricular and nodal arrhythmia Select Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Supraventricular arrhythmia Select Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4B19EA2-5900-2646-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-12","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}